25
Participants
Start Date
March 13, 2018
Primary Completion Date
October 31, 2021
Study Completion Date
July 18, 2023
DPX-Survivac
DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
Pembrolizumab
Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
Cyclophosphamide 50mg
Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Tom Baker Cancer Centre - Alberta Health Services, Calgary
Ottawa Hospital Research Institute, Ottawa
McGill University Health Centre, Montreal
Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre, Halifax
London Health Sciences Centre, London
Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto
ImmunoVaccine Technologies, Inc. (IMV Inc.)
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER